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ARTICLE

Readiness to Change and Prospective Effects of Weight
Management Programs in Pediatric Nonalcoholic Fatty
Liver Disease
Voytek Slowik1,*, Heather Wasserkrug1, Ryan T. Fischer1, Mark Connelly2, Amanda D. Deacy1,2, Sarah Hampl3 and
James F. Daniel1

Non-alcoholic fatty liver disease (NAFLD) is an increasing problem in pediatrics with limited treatment options. We prospectively assessed outcomes in patients managed in a hepatology clinic (HC) alone vs. those managed in combination with a
multidisciplinary weight management program (MWMP). We describe each group’s readiness to change at the time of NAFLD
diagnosis. Patients diagnosed with NAFLD were given a modified Stages of Change Readiness and Treatment Eagerness
Scale (SOCRATES) at enrollment (T1) to assess readiness to change. They were then followed at 3–9 months (T2) and at
10–15 months (T3). Linear mixed models were used to evaluate changes in body mass index (BMI), BMI z-score, and transaminases over time and between the two groups. There were no significant treatment group main effects or treatment × time
interactions for our primary end points for HC alone (n = 75) or with MWMP (n = 18). There was a significant main effect
for time for BMI z-score, with BMI z-scores declining on average by 0.0568 (P = 0.004) from visit to visit. Low SOCRATES
subscales scores in HC alone (n = 33) or with MWMP (n = 4) suggested a patient population with low recognition of disease
and likelihood of taking steps for change. Patients with obesity and NAFLD had low scores on all three SOCRATES subscales.
Despite this, both groups had improvement in BMI z-score without significant difference between the two treatment groups
in other primary end points. Further study is needed to identify the most effective patient selection and treatment strategies
for pediatric patients with NAFLD, including pharmacotherapy and surgery.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Multidisciplinary clinics are often used in the treatment
of obesity. Parental readiness to change is described in
the literature.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ What are the baseline characteristics, readiness
to change, and prospective outcomes for patients
seen in a hepatology clinic (HC) alone to those seen
in combination with multidisciplinary weight management program (MWMP)? Were there baseline characteristics that accounted for differences in clinical
outcomes?

Despite ongoing efforts to improve the public awareness and care of children in the United States, rates of
obesity are increasing with 18.5% of US children and
adolescents ages 2–19 years classified as obese in 2015–
2016.1,2 Decades of study have demonstrated interactions
among genetics, nutrition, physical activity, culture, and
public health policy in addition to emerging theories of
1

WHAT DOES THE STUDY ADD TO OUR KNOWLEDGE?
✔ Patients seen in an HC at a tertiary care clinic alone or
with a MWMP are both able to achieve a reduction in body
mass index z-score without significant differences between
groups. Readiness to change scores are low in a pediatric
population newly diagnosed with nonalcoholic fatty liver
disease.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?
✔ Our study highlights an area where further development of pharmacotherapy is needed to improve modest
outcomes.

infectobesity, the microbiome, circadian rhythm, and other
potential contributors.3,4 As a result, children are at increasing risk of developing metabolic syndrome, nonalcoholic
fatty liver disease (NAFLD), and premature mortality, and
complication rates increase as they become adolescents.5
Treatment options vary, but a staged approach is recommended for children and adolescents with obesity. This
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begins with counseling in the primary care setting for stage
1 and progresses to multidisciplinary services, medications, and bariatric surgery for those in stage 4 treatment.6
Multidisciplinary weight management programs (MWMPs)
have demonstrated success in weight reduction across a
range of clinical settings and are frequently used to combat
obesity at the patient level.7–9 Assessment of readiness to
change behaviors contributing to obesity is recommended
at initiation of MWMP and is often informally performed as
part of an overall motivational interviewing approach by the
clinician during office visits.10
With the increasing rates of obesity have come increasing rates of NAFLD, which is widely expected to become
the most common liver disease of childhood.11 NAFLD is
a spectrum of disease that ranges from simple steatosis
to nonalcoholic steatohepatitis and advanced fibrosis. The
etiology of NAFLD is similar to obesity; however, not all patients with obesity develop NAFLD and there are additional
intrinsic and extrinsic factors involved.12 It is currently the
second leading cause of liver transplantation in adults and
is expected to eventually become the most common.13 The
mainstay of treatment is weight management prior to the
onset of advanced fibrosis. Medications such as vitamin E
and metformin have been trialed, but results have been inconclusive and newer therapies are still under investigation.14
Patients with obesity and NAFLD are often followed by
a gastroenterologist or hepatologist to monitor complications and provide treatment. Depending on patient interest
and program availability, patients may be seen in a pediatric
hepatology clinic (HC) alone or concurrently with an MWMP.
Although the success of MWMP in weight management has
been demonstrated, outcomes have not been prospectively
compared with those resulting from care received in an HC
alone. In this study, our aims were to describe and compare
baseline characteristics, readiness to change, and prospective outcomes for patients seen in an HC alone to those
seen in combination with MWMP. In addition, we sought to
determine whether baseline characteristics accounted for
differences in clinical outcomes.
METHODS
This was an observational prospective study of pediatric
patients with NAFLD. All research activities were approved
by our institutional internal review board and proceeded in
accordance with the Helsinki Declaration of 1975. Subjects
were identified for study eligibility at their diagnostic visit for
NAFLD in the HC (T1). Subsequently, subjects were grouped
into an HC alone condition or HC with MWMP condition.
Patients were considered part of the HC with MWMP condition if they were also seen in our center’s MWMP within
6 months of their initial HC visit. Given the naturalistic design of this study, patients were not randomized into either
treatment arm; instead, referral to the MWMP was based
on provider discretion and patient interest. Age of enrollment could be 2 to 17 years. Those aged 13–17 years were
given an adapted paper-and-pencil version of the Stages
of Change Readiness and Treatment Eagerness Scale
(SOCRATES) questionnaire (SOCRATES version 8A)15,16 to
fill out after their initial clinic visit to assess for readiness to

change at diagnosis. Originally developed in the setting of
alcohol use, items were adapted by the authors of this study
to reflect patient attitudes toward their obesity and potential
health consequences (see Supplementary Material). This
adapted SOCRATES questionnaire was used because no
other age appropriate questionnaire measuring readiness
to change was available at the time of study development
(Figure S1). (Note: There is now an obesity-specific and
validated SOCRATES-OO for adults, but the current study
began before its development17.) Subjects were then followed for 2 follow-up visits in the HC at 3–9 months (T2)
and 10–15 months (T3). Patients who attended all appointments as prescribed were given a US $25 dollar gift card
for study completion. Enrollment stopped when the wait list
for the MWMP at our center grew to > 6 months. Patients
could no longer qualify for the HC with MWMP condition as
they could not be seen within 6 months of their diagnosis
of NAFLD. Primary end points included body mass index
(BMI), BMI z-score, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).
All patients referred to an HC with elevated transaminases
and obesity completed an evaluation according to current
recommendations.18 This includes screening laboratory work
and abdominal imaging to demonstrate steatosis. Screening
tests obtained per clinic protocol included antinuclear antibody, total IgG, antismooth muscle antibody, antiliver kidney
microsomal antibody, perinuclear antineutrophil cytoplasmic
antibodies, serology for hepatitis B and C, ceruloplasmin,
ferritin, total IgA, anti-tissue transglutaminase antibody IgA
level, and alpha-1-antitrypsin phenotype with other tests
ordered as needed per patient history, family history, and
clinical findings. Liver biopsy is typically reserved for cases
where the laboratory work is concerning for alternative diagnosis or for persistently elevated transaminases (> 3× upper
limit of normal over 6 months) to confirm diagnosis and
stage fibrosis, similar to EPSGHAN guidelines.18 Results
from noninvasive techniques, such as FibroScan to measure
steatosis and fibrosis) were introduced to our clinic after the
start of the study and therefore were unable to be included in
the dataset. After the initial visit, patients were scheduled for
follow-up every 3–6 months in the HC to set weight management goals, monitor changes, and assess the progression of
liver disease.
The MWMP at our center is titled Promoting Health in
Teens and Kids (PHIT Kids). The multidisciplinary team
includes physicians, nurse practitioners, psychologists, dietitians, and social workers. Patients are seen for monthly
clinic visits for treatment and monitoring of progress.
Beyond comorbidity assessment, family education, and motivational interviewing, medications, and bariatric surgery
are treatment options for qualifying patients, although surgery was not available at our institution at the start of the
study. Patients can also attend a 12-session weekly group
meeting in the evening for more intensive dietary, behavioral,
and physical activity interventions.
Statistical analysis
Participant demographic information was summarized
using descriptive statistics, and mean SOCRATES subscale scores were compared between groups using
www.cts-journal.com
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independent-samples t-tests. Preliminary analyses were
conducted to compare patients who attended routine
monthly visits in the MWMP to those who also attended
the weekly evening group meetings. We determined that
patients who attended routine monthly visits in the MWNP
were not significantly different than those who also attended weekly group meetings; as such, these two groups
were considered as one (i.e., MWMP) for all analyses. Linear
mixed effects models19,20 were used to evaluate main effects for treatment group (HC alone and HC with MWMP)
and time (T0, T1, and T2), as well as group differences in
changes because the baseline visit (group × time interaction
effect), for each of the primary outcome variables (BMI, BMI
z-score, and ALT and AST laboratory values). Models were
specified to control for baseline differences between participants in the outcome variables when evaluating changes
over time. Linear mixed effects modeling was selected for
analyses due to its capacity to validly model change in outcome variables when participants vary on the number and
spacing of completed measurement occasions.21 The linear mixed model equations were initially set up as follows:
Outcometi = 𝛽 00 + 𝛽 01 ∗ GROUPi + 𝛽 10 ∗ TIMEti + 𝛽 11 ∗ GROUPi ∗ TIMEti + r0i + 𝜀ti ,
where the outcome variable for timepoint (t) and individual
(i) is modeled as a function of the rate of change in the outcome variable for the HC alone reference group (𝛽 10) plus
any difference in rate of change for those in the HC + MWMP
group (𝛽 11), while controlling for baseline values and group
differences in those values (𝛽 00, 𝛽 01) and allowing for unaccounted for within-subject and between-subject error
(r0i + 𝜀ti). Covariates of age at diagnosis, sex, race (coded as
white vs. all others), and insurance status (public vs. private
or self-pay) also were explored in models and removed if
nonsignificant.
RESULTS
Sample characteristics
The mean age of initial HC visit was 12.6 (n = 75, SD = 2.9,
range 5–17) and 11.0 (n = 18, SD = 3.3, range 5–17) for
the HC alone and HC with MWMP treatment groups, respectively. This difference was statistically significant
(t[91] = 2.049, P = 0.043). Over half of the entire sample
(54.8%) self-identified as white, and over three-fourths of
patients (76.3%) were men; this was roughly similar in each
of the two treatment groups. Seventy-two percent of all patients had public insurance.
Of the 93 total patients, 75 were seen in an HC alone and
18 were seen in both the HC and MWMP. The mean number of
visits attended was 2.09 (n = 75, SD = 0.841) and 2.56 (n = 18,
SD = 0.616) for the HC alone and HC with MWMP treatment
groups, respectively. This difference was statistically significant (t[91] = −2.191, P = 0.031). Only 30 (40.0%) of the HC
alone group and 11 (61.1%) of the HC with MWMP attended
clinical visits at all 3 timepoints. Additionally, 13 of 75 (17.3%)
HC patients were referred to the MWMP but did not attend
their MWMP visit. Of the 18 who were seen in both the HC and
MWMP, 5 (27.8%) subjects only attended 1 visit in the MWMP.
For a more detailed summary of these results, see Table 1. No
patients received bariatric surgery (not available at the start
of the study) and only one patient in the MWMP condition received pharmacotherapy (topiramate) at a single timepoint.
Clinical and Translational Science

SOCRATES
There were 37 SOCRATES questionnaires filled out in
the HC group and 4 filled out in the MWMP group. There
were no significant differences between the two treatment
groups on any of the three SOCRATES subscales (i.e.,
recognition, ambivalence, or taking steps). Participants
reported very low recognition, indicating very low recognition of their obesity as a problem and low desire to change.
Participants also, on average, scored low on ambivalence,
suggesting that they were not ambivalent about making
changes that would result in weight loss. In other words,
because the subjects did not recognize a problem or need
for change, they were relatively certain about maintaining
their current lifestyle behaviors and equally certain about
not engaging in weight loss behaviors. Finally, participants
scored low on taking steps, reflecting a relative lack of making current changes in order to decrease their weight. For a
summary of these results, see Table 2.
Primary outcome variables – main effects and
interaction effects
There were no significant main effects for treatment group
for any of the four primary outcomes. Likewise, there were
no significant group × time interaction effects. There was,
however, a significant main effect of time for BMI z-score,
but not for AST, ALT, or raw BMI. On average, BMI z-score
decreased at a rate of −0.0625 from visit to visit for those
in the HC alone group and by −0.0408 for those in the HC
with MWMP group. Because the main effect for treatment
group and the group × time interaction term were nonsignificant in this model, the treatment group variable was
removed from a final model of BMI z-score. In this model,
the average rate of linear decrease in BMI z-score across all
participants, regardless of treatment group, was −0.0568
(P = 0.004) per visit. For a summary of these results, see
Table 3, Figure 1, and Figure S2. Covariates (age, sex,
race, and insurance status) had no significant effect in any
of the models.
DISCUSSION
Our study found small but statistically significant improvement in BMI z-score over time for patients with NAFLD
seen either in a pediatric HC alone or concurrently with
an MWMP. Both conditions offered regular medical follow-up visits to provide education, monitor adherence, and
reassess response to therapy. There were no significant
differences found among these treatment conditions. This
may indicate that some patients do not receive a benefit
from the additional resources of our MWMP if already seen
in the HC or that improved patient selection is needed to
determine who is best served by the MWMP. However, this
study does not address access to bariatric surgery (available after the study began) or pharmacotherapy (only a
single timepoint in the MWMP condition), which would be
important for future research.
A reduction in BMI z-score is an important treatment goal in
both obesity and NAFLD. This may be a better reflection of our
groups’ outcomes than raw BMI alone, as healthy BMI ranges
change with age, and suggests that both conditions achieve

1

Unknown
67
1

Public

Self-pay

25

5

More than one race
reported

Private

4
31

Hispanic/Latino

-

51

Black

-

1

-

71
22

Asian

White

-

1.1

72

26.9

1.1

53.8

33.3

4.3

1.1

54.8

23.7

76.3

6.5

5.4

14

44.1

30.1

25.8

-

-

%

-

-

-

-

-

-

-

2.09

12.56

M

-

-

-

-

-

-

-

0.84

2.93

SD

HC

HC, hepatology clinic; MWMP, multidisciplinary weight management program; NAFLD, nonalcoholic fatty liver disease.
*P < 0.05.

Insurance
status

Race

Female

Male

6

Attended weekly
MWMP intervention

13

41

28

24

93

93

n

5

-

-

-

-

0.82

3.06

SD

Total sample

Attended only 1st
MWMP visit

-

-

Attended 3 visits

Referral
patterns

Sex

-

Attended 2 visits

Referred to MWMP,
but did not attend

-

2.18

Attended 1 visit

12.25

Number of visits attended

M

Age, years at NAFLD Diagnosis

Table 1 Sample characteristics

76
1.3

1

22.7

1.3

0

33.3

5.3

1.3

58.7

25.3

74.7

-

-

17.3

40

29.3

30.7

-

-

%

57

17

1

0

25

4

1

44

19

56

-

-

13

30

22

23

75

75

n

-

-

-

-

-

-

-

2.56

10.94

M

-

-

-

-

-

-

-

0.62

3.32

SD

MWMP

0

10

8

0

5

6

0

0

7

3

15

6

5

-

11

6

1

18

18

n

0

55.6

44.4

0

27.8

33.3

0

0

38.9

16.7

83.3

33.3

27.8

-

61.1

33.3

5.6

-

-

%

-

-

-

-

-

-

-

0.031*

0.043*

Significance,
P value

Pediatric NAFLD and Weight Management
Slowik et al.
585

www.cts-journal.com

Pediatric NAFLD and Weight Management
Slowik et al.
586
Table 2 SOCRATES subscale scores
HC
(n = 33)

Total sample (n = 37)

Subscale

M

SD

MWMP
(n = 4)

M

SD

M

SD

Significance,
P-value

Recognition

24.32

20.21

24.55

20.01

22.50

25.00

0.852

Ambivalence

39.73

24.21

40.91

25.05

30.00

14.14

0.402

Taking Steps

37.57

25.76

38.18

26.63

32.50

18.93

0.683

HC, hepatology clinic; MWMP, multidisciplinary weight management program; SOCRATES, Stages of Change Readiness and Treatment Eagerness Scale.

an important treatment outcome. Raw BMI and transaminases
were found to not decrease significantly regardless of group
or to vary in amount of change between the two conditions.
Several reasons for this may exist. The BMI z-score may better
reflect patients’ weight outcomes than BMI alone. In addition,
it has also been demonstrated that transaminase elevations
themselves do not accurately predict fibrosis in pediatric
NAFLD.22 With a reduction in BMI z-score, our patients may
have a reduction in steatosis or slowing of fibrosis not seen
with noninvasive testing. Further improvements in steatosis
may eventually lead to a clinically significant normalization
of transaminases. It is important to note that the change in
BMI z-score was small, but our results reflect a linear reduction in BMI z-score per unit of time. Based on our model, BMI
z-score was predicted to continue to improve with each visit
and cumulative effects may be more clinically significant.
Given the difficulty achieving successful weight reduction with
nonsurgical treatment, we felt that this result was still clinically
significant despite the small change per visit over time.
In our study, the amount of readiness to change could
not be distinguished between the two groups. However,
it remains an important characteristic in this population.
Readiness to change was found in Brazilian child and adolescent patients to be associated with increased improvement
in anthropometrics, hemodynamics, and cardiorespiratory
fitness.23 National organization recommendations10 and literature reviews24,25 support assessment of this construct
as well. Our results may reflect a patient population less
prepared to actively change their lifestyle behaviors than
clinicians perceive, and more realistic behavioral goals may
need to be collaboratively set with the family.
The current study possesses several strengths worthy of
mention. It is the first study to prospectively compare treatment
outcomes of pediatric NAFLD with HC alone or in combination

with an MWMP over an extended period. Other published
studies have followed children with obesity and NAFLD over
similar time frames, but have not compared hepatology follow-up alone and MWMP treatments.26 Additionally, we
formally evaluated patient readiness to change in our sample,
an important construct in the obesity treatment literature.25
We found that BMI z-score improved in our population with
regular follow-up despite having lower readiness to change,
reinforcing that regular treatment sessions are associated
with improved weight outcomes, perhaps due to monitoring
alone27 or regression to the mean.28 As providers establish
their clinic structure, our study reveals the possibility that BMI
z-score can improve either in HC alone or in combination with
an MWMP. These results can impact program infrastructure
as providers assess their available local resources to expand
either their HC or MWMP. The naturalistic nature of our study
design also offered us the ability to describe our patient’s real-time appointment adherence patterns. Attrition played a
significant role in both groups, and—along with assessment
of readiness for change—needs to be a target of future studies.25 Increasing patient retention is an important target for
future therapies.
These strengths notwithstanding, our study has limitations that warrant discussion. Treatment groups were based
on provider or patient preference without randomization or
controlling for therapies. This naturalistic design may lead to
unknown confounders normally addressed through randomization. There may be inherent characteristics in those who
choose or do not choose to attend an MWMP that could affect results. Effects of this can be seen in the total number
of SOCRATES questionnaires filled out in the HC alone and
MWMP groups. Parental readiness to change was not assessed in our study, although it may influence our results.
The role of caregivers in the pediatric obesity population is

Table 3 Results of linear mixed effects model for primary outcome variables
Initial status
[95% CI]

Group effect
[95% CI]

34.74* [32.51, 36.96]

−3.80 [−8.84, 1.24]

−0.64 [−1.77, 0.50]

1.73 [−4.8, 3.94]

2.38* [2.30, 2.46]

0.11 [−0.08, 0.29]

−0.06* [−0.11, −0.02]

0.02 [−0.07, 0.11]

ALT

107.37* [92.53, 122.20]

−2.44 [−36.60, 31.72]

−2.33 [−20.43, 15.78]

−8.11 [−43.67, 27.45]

AST

57.62* [49.75, 65.48]

11.59 [−11.66, 34.84]

3.20 [−8.56, 14.96]

−12.10 [−35.82, 11.63]

Outcome
BMI
BMI z-score

Time effect
[95% CI]

Group × time interaction
[95% CI]

*Statistically significantly different from 0, P < 0.05. Initial status is the estimated average baseline value of the outcome variable for the HC group, and the
group effect represents the estimated difference in this average baseline value associated with the MWMP group. The time main effect is the estimated average change in the outcome variable from visit to visit for the HC group, and the group × time interaction effect is the estimated difference in this average rate
of change associated with the MWMP group.
ALT, alanine aminotransferase; ALT, aspartate aminotransferase; BMI, body mass index; CI, confidence interval.
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Figure 1 Comparison of mean body mass index (BMI)z-score changes over time for the hepatology clinic alone (HC, ○) and those
seen with a multidisciplinary weight management program (MWMP, □).

increasingly garnering clinical and research interest. Parents
have been found to be more ready for dietary changes in
children but less so for physical activity changes in older
children.29 Parental perception of their own weight affects parental readiness to change both positively and negatively.29,30
Interestingly, parental readiness to change, readiness for
treatment, and ratings of importance have not been found
to predict success in the treatment of obesity.31,32 Given that
caregivers frequently control the access to food and physical
activities, future studies should be undertaken to identify the
most effective parental factors and interventions for success.
Attrition was significant in our study, with many patients
lost to follow-up in the HC or to their MWMP appointments
despite enrollment into our study (Table 1). This attrition furthered the divide in sample sizes between the two groups
as well as SOCRATES questionnaire completion and may
introduce bias. Attrition is a known feature of this population.33 Previous studies have shown that as many as 58.8%
of patients do not attend their initial referral to an MWMP.34
After evaluation, 47% of patients do not return for a second
MWMP visit.35 Our center uses a combination of electronic,
physical mail, and telephone reminders in attempts to decrease attrition. However, further study is needed to identify
effective strategies to improve retention in this population,
which can improve access to care.
BMI and BMI z-score are frequent indicators of outcome
in MWMP, but it is important to consider that these measures are not the sole target. A recent study by Luca et al.
of the SickKids Team Obesity Management Program found
that BMI did not decrease significantly compared with a control adolescent group with obesity not seen in an MWMP.36

However, the group seen in the MWMP did have improvements in cardiometabolic, psychological, and health behavior
outcomes.36 Although our study did not find significant differences in transaminases, findings such as Luca et al.’s highlight
the need for comprehensive and multidisciplinary evaluation
of clinical outcomes in this population. Additionally, our study
was limited by lack of access to noninvasive techniques to
monitor steatosis and fibrosis, such as FibroScan, which will
be important in future studies, as serial liver biopsy is difficult
to clinically justify in this patient population.
As obesity rates in the United States continue to worsen,
further study is required to address the optimal treatment strategies in this patient group. The US Preventive Services Task
Force reported that moderate to high intensity (> 26 hours)
comprehensive behavioral interventions are associated with
durable improvements in weight status. To aid in weight management, there is emerging interest in the development of
pharmacotherapy to treat pediatric obesity.37 Although adult
pharmacotherapy is already in use, pediatric medications
are increasingly utilized for weight management. Indeed, our
results may be part of a call for the further development of
pharmacologic intervention given the modest improvement in
outcomes of both HC and MWMP. Bariatric surgery is becoming more widespread in the United States to treat pediatric
obesity for those who need further treatment.35 It has been
found to be safe and effective and is most often offered to
pediatric patients in the setting of a tertiary care MWMP.
These treatment options may be among the most important
factors in determining a referral to an MWMP. Last, patient
level therapies may be ineffective to manage this crisis across
the nation. The surge in obesity reflects a complex interplay
www.cts-journal.com
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among patient level characteristics, culture, and public policy
that influence patient behaviors, such as agricultural subsidies.38 It may be more cost effective to promote public health
policies to demonstrate cost savings and prevention of cases
of childhood obesity.39
Our results suggest that, despite low readiness to change,
our pediatric patients with NAFLD demonstrated statistically
significant improvement in BMI z-score over time without
collateral changes in BMI, AST, and ALT. This argues that
future study is needed to identify the most effective means
of engaging and maintaining adolescents with obesity and
NAFLD in treatment, including refinement of HC, MWMP,
pharmacotherapy, and bariatric surgery.
Supporting Information. Supplementary information accompanies this paper on the Clinical and Translational Science website (www.
cts-journal.com).
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